
Please try another search
(Reuters) - Empowered Diagnostics LLC is recalling its COVID-19 tests as they have not been cleared for use in the United States and could potentially lead to false results, the U.S. Food and Drug Administration (FDA) said on Friday.
The regulator has labeled the recall of the CovClear COVID-19 rapid antigen test and the ImmunoPass COVID-19 neutralizing antibody rapid test as Class 1, or the most serious type of recall.
It cautioned people to stop using the two tests, which have been distributed with labeling that incorrectly indicates that they are authorized by the FDA.
The company could not be immediately reached for comment.
Empowered Diagnostics initiated the recall in December and has pulled back at least 284,575 antigen tests and 2,100 antibody tests in the United States, according to the regulator.
The CovClear test is currently authorized in Canada and the European Union, according to the company's website.
By Nancy Lapid (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that...
By Leroy Leo and Michael Erman (Reuters) - The U.S. Food and Drug Administration has decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying that the...
By SungHyuk An and Heejung Jung SEOUL (Reuters) - Standing tall in bright red hazmat suits, five North Korean health workers stride towards an ambulance to do battle with a...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.